6533b7dbfe1ef96bd1270079

RESEARCH PRODUCT

Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma

A. ChanA. AnbuselvanS.s. UpadhyayulaS. JemimahP. JaynesM.m. HoppeJ.d. WardynJ. GohG. BertolazziM. FoianiM.j. O’connorE.k. ChowC. TripodoA.d. Jeyasekharan

subject

Cancer ResearchOncologyDLBCL DNA damage chemotherapySettore MED/42 - Igiene Generale E ApplicataSettore MED/01 - Statistica Medica

description

Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.

yearjournalcountryeditionlanguage
2022-10-01
10.1016/s0959-8049(22)00949-2https://hdl.handle.net/10447/581690